Identification | Back Directory | [Name]
3-azaspiro[5.5]undecane hydrochloride | [CAS]
1125-01-5 | [Synonyms]
3-Azaspiro[5.5]undecane HCl 4,4-Pentamethylenepiperidine 9-azaspiro[5.5]undecane chloride 3-azaspiro[5.5]undecane hydrochloride | [EINECS(EC#)]
214-404-1 | [Molecular Formula]
C10H20ClN | [MDL Number]
MFCD02093801 | [MOL File]
1125-01-5.mol | [Molecular Weight]
189.726 |
Chemical Properties | Back Directory | [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
Soluble to 100 mM in water and to 100 mM in DMSO | [form ]
Powder | [color ]
White to off-white |
Hazard Information | Back Directory | [Uses]
4,4-Pentamethylenepiperidine Hydrochloride is a M2 proton channel blocker. Inhibits influenza virus M2 protein (AM2). | [Uses]
A M2 proton channel blocker. Inhibits influenza virus M2 protein (AM2). | [Synthesis]
The synthesis of BL-1743 started with 3,3-cyclopentane glutarimide, which was first subjected to a reductive reaction with lithium aluminum hydride (LiAlH4) in tetrahydrofuran (THF) under refluxing conditions to afford 3-azaspiro[5,5]undecane hydrochloride (9), which was followed by treatment with HCl/ethyl ether to obtain the target product in 75% yield (see Scheme 1). Next, model compound BL-1743 was prepared by nucleophilic substitution of compound 9 by 2-methylthio-2-imidazoline.In addition, compound 9 was subjected to reductive amination with different aldehydes in dichloroethane using sodium triacetoxyborohydride (NaBH(OAc)3) and formic acid (HCO2H) as reducing agents to afford derivatives 1-8 in yields ranging from 65% to 95%. The results of activity tests showed that the inhibitory activity of BL-1743 was completely lost at 100 μM concentration after the imidazoline ring was replaced by a hydrophobic substituent or a heterocyclic ring that lacked a hydrogen bond donor (HBD), and the AM2 activity remained >90%. In contrast, inhibitors 7 and 8 containing an imidazole head group showed moderate inhibitory activity, suggesting that the presence of a hydrogen bond donor may be a structural feature necessary for inhibitory activity. | [References]
[1] Patent: US2010/69420, 2010, A1. Location in patent: Page/Page column 7 |
|
Company Name: |
BOC Sciences
|
Tel: |
1-631-485-4226; 16314854226 |
Website: |
https://www.bocsci.com |
|